Answers are grounded in this paper and cite their sources.
Single-case trial examines cognitive-behavioral therapy and GIP/GLP-1 for binge-eating disorder, suggesting a combined treatment approach may be effective.
Objective Many patients with larger bodies present to eating disorder (ED) treatment seeking weight loss. Whether glucose‐dependent insulinotropic polypeptide/glucagon‐like‐peptide receptor agonists (GIP/GLP‐1s) are helpful or harmful for such patients remains unknown. This single case experimental design study examined the effects of Tirzepatide (7.5 mg/0.05 mL), a GIP/GLP‐1 following 10‐session cognitive‐behavioural therapy (CBT‐T) in a patient with binge‐eating disorder (BED) and obesity. Method A 37‐year‐old female presented to an outpatient ED clinic with BED and a body mass index of 68.9 kg/m 2 . We assessed weekly and then monthly ED behaviours and cognitions using the Eating Disorder 15 (ED‐15) across two treatment phases: CBT‐T (3 months) and GIP/GLP‐1 administration (9 months). Results As hypothesised, ED cognitions and binge frequency decreased during CBT‐T. Also as hypothesised, during GIP/GLP‐1 phase, binge frequency remained low and dietary restraint absent. We observed continued reductions in ED cognitions and 39‐pound weight loss. Discussion GIP/GLP‐1 treatment after CBT‐T was followed by ED remission and weight loss without serious adverse events. CBT‐T skills may mitigate risk of disordered eating during GIP/GLP‐1 use. The combination of psychotherapy and GIP/GLP‐1s may further reduce binge‐eating and lead to weight loss. Research is needed to explore risks and benefits of GIP/GLP‐1s for patients with EDs.
No takes yet. Share an insight, caveat, or question.
Dunford et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: